Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL

Jonathan Brammer, MD

Published: Thursday, Nov 09, 2017

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).

SELECTED
LANGUAGE

SEE ALL VIDEOS FROM: Jonathan Brammer, MD

View more on OncLive TV >>>

Trending Now

Statistics Show Increase in US Cancer Survivors

Expert Highlights Need for Widespread Liquid Biopsy Use in Lung Cancer Treatment

Molecular Testing Continues to Evolve in Ovarian Cancer

Dr. El-Khoueiry on Choosing Between Immunotherapy Agents and TKIs in HCC

Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer

Woyach Highlights Long-Term Acalabrutinib/Obinutuzumab Data in CLL

Ibrutinib Established as Standard for Older CLL Patients

New Data Further Demonstrate PARP Inhibitor Impact in Ovarian Cancer

Novel Combination Shows Early Efficacy in Ovarian Cancer

Related Videos

Dr. Woyach on 3-Year Follow-Up of Acalabrutinib/Obinutuzumab Combo in CLL

Dr. O'Malley on Folate-Receptor Alpha as a Biomarker in Ovarian Cancer

Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

Dr. Rogers on Reducing Risk of Tumor Lysis Syndrome in CLL

View Conference Coverage

2019 State of the Science Summit on Genitourinary Cancers in Jacksonville

2019 State of the Science Summit on Hematologic Malignancies in Pittsburgh

2019 State of the Science Summit on Hematologic Malignancies in Seattle

15th International Conference on Malignant Lymphoma

Online CME Activities

Title	Expiration Date	CME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology Strategies	Jul 30, 2019	1.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?	Jul 31, 2019	1.5